BIIB
Biogen Inc. · Healthcare
172.77
0.25%(+0.43)
Market OpenLast Updated: — ET
52W L: $110.0452W H: $202.41
$171.03
CHG-12.06 (-6.59%)
H$194.00
L$168.26
VOL17M
BIIB (1h)
Biogen Inc. · Healthcare
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy's novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligibl.
Management aims to book a $34 million charge in the quarter. This is due to loftier anticipated spend on items such as milestone payments and research and development activities.
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Element Squared LLC bought a new stake in shares of Biogen Inc. (NASDAQ: BIIB) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 15,051 shares of the biotechnology company's stock, valued at approximately $2,649,000. Biogen makes up approximately 1.4% of Element Squared LLC's
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
Burns Matteson Capital Management LLC bought a new position in Biogen Inc. (NASDAQ: BIIB) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 3,919 shares of the biotechnology company's stock, valued at approximately $690,000. Other hedge funds have also recently made changes to their positions
Godbout Sean
officer: Chief Accounting Officer
181 SH @ $0.00
2026-04-01
Godbout Sean
officer: Chief Accounting Officer
54 SH @ $183.78
2026-04-01
Godbout Sean
officer: Chief Accounting Officer
181 SH @ $0.00
2026-04-01
Viehbacher Christopher
director, officer: President and CEO
38,015 SH @ $0.00
2026-02-13
Singhal Priya
officer: Head of Development
10,560 SH @ $0.00
2026-02-13
Murphy Nicole
officer: Head of Pharm Ops and Tech
3 SH @ $195.03
2026-02-12
Murphy Nicole
officer: Head of Pharm Ops and Tech
10,560 SH @ $0.00
2026-02-13
Kramer Robin
officer: Chief Financial Officer
8,450 SH @ $0.00
2026-02-13